Patent · US Active

Use of VEGF in the treatment of retarded fetal growth in pregnancy

US8334271B2 · kind B2 · utility

0Cited by

1References

3Claims

0Family size

Assignee

ARK THERAPEUTICS, LTD. · GB

Inventors

John Francis Martin · Danvers, US
Charles Henry Rodeck · London, GB

Key dates

Filing date	Feb 22, 2008
Grant date	Dec 18, 2012
Priority date	—
Expiry date	Oct 18, 2028

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P15/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

An agonist of the VEGF receptor is useful in the treatment of a disease associated with retarded fetal growth, such as intra-uterine growth retardation. The VEGF agonist may be a VEGF peptide or a gene construct encoding or expressing such a peptide.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.